Trial Profile
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Benralizumab (MEDI-563) in Reducing Eosinophilia in Subjects With Hypereosinophilic Syndrome (HES)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary)
- Indications Hypereosinophilic syndrome
- Focus Therapeutic Use
- Acronyms HESIL5R
- 26 Feb 2024 Results (n=14) of Long-term Efficacy and Safety of Benralizumab Treatment , presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 10 Sep 2021 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 04 Dec 2019 Planned End Date changed from 1 Jun 2020 to 31 Dec 2022.